Category / Industry news

eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May 30, 2023 – eXmoor pharma, the end-to-end cell and gene therapy (CGT) manufacturing partner, today announced the close of a…

eXmoor pharma and vaccine developer Imophoron sign process development partnership Multi-phase partnership will aim to manufacture vaccines for clinical use in eXmoor’s new facility to be launched in Q3, 2023 Bristol, UK, February 22, 2023 – eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and…

eXmoor to present at OBN BioTuesday: 'A Spotlight on the Latest Research and Innovation In Cell & Gene Therapy' - 21 February eXmoor are delighted to participate in OBN's upcoming  BioTuesday event on 21 February, spotlighting 'Latest Research and Innovation In Cell & Gene Therapy'. During the evening, we will hear from some key thought…

eXmoor Pharma appoints CTO as part of ambitious expansion strategy Lucy Foley joins eXmoor after eight years at the Centre for Process Innovation (CPI) with her most recent position as Director of Biologics and COVID response. Bristol, 9th February 2022 - Bristol based, eXmoor Pharma is pleased to announce the appointment of Dr. Lucy Foley…

eXmoor Pharma secures contract to work with New Zealand Blood Service This will be eXmoor’s first project in the Australasia region. The UK-based delivery team has adapted its working processes to allow for collaborative communication across time zones with the NZBS team. 11 January 2021: eXmoor Pharma, experts in strategic and technical biomanufacturing, specialising in…